Evidence map›Paper›PMID 39769077›Full record

ArticleInternational journal of molecular sciences2024

Efficacy of Cystic Fibrosis Transmembrane Regulator Corrector C17 in Beta-Sarcoglycanopathy-Assessment of Patient's Primary Myotubes.

Martina Scano, Alberto Benetollo, Francesco Dalla Barba, Eylem Emek Akyurek, Marcello Carotti, Roberta Sacchetto, Dorianna Sandonà

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. [European journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Martina ScanoDepartment of Biomedical Sciences, University of Padova, Via U. Bassi 58/B, 35131 Padova, Italy.ORCID 0000-0002-8761-1730
Alberto BenetolloDepartment of Biomedical Sciences, University of Padova, Via U. Bassi 58/B, 35131 Padova, Italy.ORCID 0000-0002-1848-0677
Francesco Dalla BarbaDepartment of Biomedical Sciences, University of Padova, Via U. Bassi 58/B, 35131 Padova, Italy.ORCID 0009-0008-3277-4242
Eylem Emek AkyurekDepartment of Comparative Biomedicine and Food Science, University of Padova, Agripolis, Legnaro, 35020 Padova, Italy.ORCID 0000-0002-7054-5116
Marcello CarottiDepartment of Biomedical Sciences, University of Padova, Via U. Bassi 58/B, 35131 Padova, Italy.ORCID 0000-0002-7742-339X
Roberta SacchettoDepartment of Comparative Biomedicine and Food Science, University of Padova, Agripolis, Legnaro, 35020 Padova, Italy.ORCID 0000-0001-8884-8302
Dorianna SandonàDepartment of Biomedical Sciences, University of Padova, Via U. Bassi 58/B, 35131 Padova, Italy.ORCID 0000-0002-9908-2442

Funding

Association Françoise contre les Myopathies #18620, #23000, #28892Italian Telethon Foundation GGP15140, GGP20097Muscular Dystrophy Association #MDA 577888, https://doi.org/10.55762/pc.gr.81540
6 · The paper itself

Abstract

Limb-girdle muscular dystrophy type 2E/R4 (LGMD2E/R4) is a rare disease that currently has no cure. It is caused by defects in the

Indexed as

Cystic Fibrosis Transmembrane Conductance RegulatorMuscle Fibers, SkeletalSarcoglycanopathiesSarcoglycansHEK293 CellsHumansMuscular Dystrophies, Limb-GirdleMutation, MissenseProteasome Endopeptidase ComplexProteolysisSarcolemmaCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorProteasome Endopeptidase ComplexSarcoglycansERADLGMD2D/R3LGMD2E/R4missense mutationsmyotubespathogenic mechanismpatient-derived cellssmall moleculesubiquitin–proteasome system

Identifiers

PMID39769077
PMCPMC11676211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.